Therapeutic Trial of Lipid X in a Canine Model of Septic Shock

Robert L. Danner, Peter Q. Eichacker, Martin E. Doerfler, William D. Hoffman, Joseph Reilly, J. H. P. Wilson, Thomas J. MacVittie, P. STUETZ, Joseph E. Parrillo, Charles Natanson

The Journal of Infectious Diseases · 1993 · 22 citations · 34 references

Concepts

Abstract

Three groups of dogs were given lipid X (0, 1, or 10 mg/kg) every 8 h for for seven doses, starting simultaneously with the intraperitoneal placement of Escherichia coli-containing fibrin clots. All animals developed bacteremia, hypotension, and a pattern of decreased left ventricular ejection fraction characteristic of septic shock (P = .01). Survival rates and survival times were not significantly different between treatment groups (P > .2). In a similar experiment, higher doses of lipid X resulted in a significantly decreased survival time compared with concurrent controls (P = .04). Animals receiving lipid X did not differ from controls in serial determinations of temperature, hemodynamic measurements, or laboratory parameters (except serum total protein). Although lipid X has antiendotoxin effects, no benefit could be demonstrated in this antibiotic-treated, gram-negative bacillary-infected model of septic shock. These data do not support a therapeutic role for lipid X in the treatment of gram-negative sepsis.

References

34